Key takeaways
Infliximab (Remicade) and upadacitinib (Rinvoq) are both medications used to treat autoimmune conditions like rheumatoid arthritis (RA) and ulcerative colitis (UC). However, they belong to different medication classes. Infliximab is a biologic disease-modifying antirheumatic drug (DMARD) that works by blocking tumor necrosis factor (TNF) to reduce inflammation. It is administered as an intravenous (IV) infusion by a healthcare professional. Upadacitinib, on the other hand, is a Janus kinase (JAK) inhibitor taken orally, either as a tablet or liquid. It blocks the JAK enzyme to lower inflammation. Infliximab is also used for conditions like Crohn's disease and severe plaque psoriasis, while upadacitinib is used for eczema and non-radiographic axial spondyloarthritis, among others. Both medications are only available as brand-name products, but Remicade has biosimilars like Avsola, Inflectra, and Renflexis available. Common side effects of infliximab include infections and infusion-related reactions, while upadacitinib can cause acne and upper respiratory tract infections. Both medications can increase the risk of serious infections, but infliximab also has a risk of heart problems and liver issues, while upadacitinib may cause blood clots and stomach tears.
